{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:35:14Z","timestamp":1790969714068,"version":"4.1.0"},"reference-count":46,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>We have previously reported that teriparatide is associated with substantial increases in bone mineral density (BMD) at the lumbar spine (LS), total hip (TH), and femoral neck (FN) and small declines at the distal radius in 41 premenopausal women with idiopathic osteoporosis (IOP), all severely affected with low trauma fractures and\/or very low BMD. Effects of teriparatide dissipate if not followed by antiresorptives.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the effects of 12 and 24 months of denosumab in premenopausal women with IOP completing 24 months of teriparatide.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a preplanned phase 2B extension study. Premenopausal women with IOP who had completed a course of teriparatide received denosumab 60 mg every 6 months over 24 months. The main outcome measure was within-group change in BMD at the LS at 12 months. Secondary outcomes include change in 12-month BMD at other sites, 24-month BMD at all sites, trabecular bone score (TBS), and bone turnover markers (BTMs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After completing teriparatide, 32 participants took denosumab for 12 months and 29 for 24 months, with statistically significant increases in BMD at the LS (5.2 \u00b1 2.6% and 6.9 \u00b1 2.6%), TH (2.9 \u00b1 2.4% and 4.6 \u00b1 2.8%), and FN (3.0 \u00b1 3.8% and 4.7 \u00b1 4.9%). Over the entire 24-month teriparatide and 24-month denosumab treatment period, BMD increased by 21.9 \u00b1 7.8% at the LS, 9.8 \u00b1 4.6% at the TH, and 9.5 \u00b1 4.7% at the FN (all P &amp;lt; .0001). TBS increased by 5.8 \u00b1 5.6% (P &amp;lt; .001). Serum BTM decreased by 75% to 85% by 3 months and remained suppressed through 12 months of denosumab. Denosumab was generally well tolerated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These data support the use of sequential teriparatide and denosumab to increase BMD in premenopausal women with severe osteoporosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab850","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T03:57:29Z","timestamp":1638331049000},"page":"e1528-e1540","source":"Crossref","is-referenced-by-count":43,"title":["Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis"],"prefix":"10.1210","volume":"107","author":[{"given":"Elizabeth","family":"Shane","sequence":"first","affiliation":[{"name":"Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Shiau","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R","family":"Recker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Creighton University Medical Center, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan M","family":"Lappe","sequence":"additional","affiliation":[{"name":"Department of Medicine, Creighton University Medical Center, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanchita","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafo","family":"Kamanda-Kosseh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Bucovsky","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Stubby","sequence":"additional","affiliation":[{"name":"Department of Medicine, Creighton University Medical Center, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0641-5747","authenticated-orcid":false,"given":"Adi","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"issue":"1","key":"2022052023084494400_CIT0001","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00198-011-1560-y","article-title":"Premenopausal women with idiopathic low-trauma fractures and\/or low bone mineral density","volume":"23","author":"Cohen","year":"2012","journal-title":"Osteoporos Int."},{"issue":"1","key":"2022052023084494400_CIT0002","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/jwh.2008.0887","article-title":"Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center","volume":"18","author":"Cohen","year":"2009","journal-title":"J Womens Health (Larchmt)."},{"issue":"10","key":"2022052023084494400_CIT0003","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1210\/jc.2011-1387","article-title":"Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis","volume":"96","author":"Cohen","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2022052023084494400_CIT0004","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1210\/jc.2012-2099","article-title":"Central QCT reveals lower volumetric BMD and stiffness in premenopausal women with idiopathic osteoporosis, regardless of fracture history","volume":"97","author":"Cohen","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2022052023084494400_CIT0005","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1210\/jc.2009-0996","article-title":"Bone microarchitecture and stiffness in premenopausal women with idiopathic osteoporosis","volume":"94","author":"Cohen","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2022052023084494400_CIT0006","doi-asserted-by":"crossref","first-page":"e3540","DOI":"10.1210\/clinem\/dgaa489","article-title":"Effect of teriparatide on bone remodeling and density in premenopausal idiopathic osteoporosis: a phase II trial","volume":"105","author":"Cohen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2022052023084494400_CIT0007","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1210\/jc.2013-1172","article-title":"Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study","volume":"98","author":"Cohen","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"9999","key":"2022052023084494400_CIT0008","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet."},{"issue":"4","key":"2022052023084494400_CIT0009","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jocd.2017.05.007","article-title":"Effects of teriparatide, denosumab, or both on spine trabecular microarchitecture in DATA-Switch: a randomized controlled trial","volume":"20","author":"Tsai","year":"2017","journal-title":"J Clin Densitom."},{"issue":"10","key":"2022052023084494400_CIT0010","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/jbmr.3198","article-title":"Effects of denosumab and teriparatide transitions on bone microarchitecture and estimated strength: the DATA-Switch HR-pQCT study","volume":"32","author":"Tsai","year":"2017","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2022052023084494400_CIT0011","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jbm4.10054","article-title":"Efficacy of switching from teriparatide to bisphosphonate or denosumab: a prospective, randomized, open-label trial","volume":"2","author":"Niimi","year":"2018","journal-title":"JBMR Plus."},{"issue":"11","key":"2022052023084494400_CIT0012","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1210\/jc.2015-2829","article-title":"Bone density after teriparatide discontinuation in premenopausal idiopathic osteoporosis","volume":"100","author":"Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2022052023084494400_CIT0013","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1210\/jc.2011-1387","article-title":"Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis","volume":"96","author":"Cohen","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2022052023084494400_CIT0014","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1210\/jc.2006-1178","article-title":"Clinical review: clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry","volume":"91","author":"Lewiecki","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022052023084494400_CIT0015","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jocd.2011.05.005","article-title":"Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae","volume":"14","author":"Hans","year":"2011","journal-title":"J Clin Densitom."},{"issue":"3","key":"2022052023084494400_CIT0016","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/jbmr.2176","article-title":"Trabecular bone score: a noninvasive analytical method based upon the DXA image","volume":"29","author":"Silva","year":"2014","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2022052023084494400_CIT0017","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jocd.2019.07.006","article-title":"Dual-energy X-ray Absorptiometry Monitoring with Trabecular Bone Score: 2019 ISCD Official Position","volume":"22","author":"Krohn","year":"2019","journal-title":"J Clin Densitom."},{"issue":"5","key":"2022052023084494400_CIT0018","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/jbmr.2734","article-title":"A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX","volume":"31","author":"McCloskey","year":"2016","journal-title":"J Bone Miner Res."},{"issue":"19","key":"2022052023084494400_CIT0019","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"issue":"9","key":"2022052023084494400_CIT0020","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2022052023084494400_CIT0021","first-page":"3069","article-title":"Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers","volume":"85","author":"Kurland","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2022052023084494400_CIT0022","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00198-009-0917-y","article-title":"Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status","volume":"20","author":"Langdahl","year":"2009","journal-title":"Osteoporos Int."},{"key":"2022052023084494400_CIT0023","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bone.2018.07.013","article-title":"Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: integrated analysis of 4 prospective observational studies","volume":"116","author":"Langdahl","year":"2018","journal-title":"Bone."},{"issue":"20","key":"2022052023084494400_CIT0024","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med."},{"issue":"2","key":"2022052023084494400_CIT0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jbmr.3359","article-title":"An essential warning: editorial on vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial, its extension","volume":"33","author":"Leder","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2022052023084494400_CIT0026","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","article-title":"Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and teriparatide follow-up study (DATA-Follow-up)","volume":"98","author":"Leder","year":"2017","journal-title":"Bone."},{"issue":"5","key":"2022052023084494400_CIT0027","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int."},{"issue":"5","key":"2022052023084494400_CIT0028","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporos Int."},{"issue":"4","key":"2022052023084494400_CIT0029","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int."},{"key":"2022052023084494400_CIT0030","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bone.2015.06.007","article-title":"TBS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures","volume":"79","author":"Muschitz","year":"2015","journal-title":"Bone."},{"key":"2022052023084494400_CIT0031","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bone.2015.05.016","article-title":"Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice","volume":"78","author":"Harvey","year":"2015","journal-title":"Bone."},{"issue":"9","key":"2022052023084494400_CIT0032","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.39726","article-title":"trabecular bone score in patients with chronic glucocorticoid therapy-induced osteoporosis treated with alendronate or teriparatide","volume":"68","author":"Saag","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"2022052023084494400_CIT0033","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00198-014-2703-8","article-title":"Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study","volume":"25","author":"Senn","year":"2014","journal-title":"Osteoporos Int."},{"issue":"2","key":"2022052023084494400_CIT0034","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-017-4304-9","article-title":"Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial","volume":"29","author":"Bilezikian","year":"2018","journal-title":"Osteoporos Int."},{"issue":"12","key":"2022052023084494400_CIT0035","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jama.280.12.1067","article-title":"Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial","volume":"280","author":"Finkelstein","year":"1998","journal-title":"JAMA."},{"issue":"4","key":"2022052023084494400_CIT0036","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1210\/jc.2013-4105","article-title":"Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa","volume":"99","author":"Fazeli","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022052023084494400_CIT0037","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J Clin Invest."},{"issue":"5","key":"2022052023084494400_CIT0038","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/cen.13557","article-title":"changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis","volume":"88","author":"Hong","year":"2018","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"6","key":"2022052023084494400_CIT0039","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1210\/jc.2004-2042","article-title":"Low bone formation in premenopausal women with idiopathic osteoporosis","volume":"90","author":"Donovan","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"9886","key":"2022052023084494400_CIT0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet."},{"issue":"7","key":"2022052023084494400_CIT0041","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.2016.11032","article-title":"Osteoporosis therapy in postmenopausal women with high risk of fracture","volume":"316","author":"Cappola","year":"2016","journal-title":"JAMA."},{"key":"2022052023084494400_CIT0042","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev-med-052218-020620","article-title":"New frontiers in osteoporosis therapy","volume":"71","author":"Cheng","year":"2020","journal-title":"Annu Rev Med."},{"issue":"4","key":"2022052023084494400_CIT0043","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/BOR.0000000000000616","article-title":"The evolving role of anabolic therapy in the treatment of osteoporosis","volume":"31","author":"Cosman","year":"2019","journal-title":"Curr Opin Rheumatol."},{"issue":"2","key":"2022052023084494400_CIT0044","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/jbm4.10041","article-title":"Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy","volume":"2","author":"Leder","year":"2018","journal-title":"JBMR Plus."},{"issue":"8","key":"2022052023084494400_CIT0045","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2022052023084494400_CIT0046","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab850\/41877795\/dgab850.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/4\/e1528\/43775497\/dgab850.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/4\/e1528\/43775497\/dgab850.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T23:09:23Z","timestamp":1653088163000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/4\/e1528\/6437931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,11,24]]},"published-print":{"date-parts":[[2022,3,24]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab850","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,11,24]]}}}